Medication, possessing hepatoprotective, detoxicating and regenerating action

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry, namely to creation of medication, which possesses hepatoprotective, detoxicating and regenerating action. Medication contains in its composition essential phospholipids, vitamin B1, vitamin B2, vitamin B6, vitamin E, extract of milk thistle, extract of artichoke and auxiliary substances. Claimed medication extends arsenal of hepatoprotective medications, which possess wide pharmacologic spectrum of action.

EFFECT: medication corresponds to polyvalency of disease pathogenesis, affects patient's organism as a whole as corrective system.

2 ex, 3 tbl

 

The invention relates to medicine and pharmaceuticals, and in particular to means on the basis of medicinal plants with hepatoprotective and choleretic action.

Diseases of liver and biliary system occupy a significant place in the overall morbidity of the population worldwide. In Russia they suffer approximately every 20 resident. The most important reason for this is the long-term effects on the liver of various toxic agents in connection with the use of chemicals in industry and agriculture, medicine and food intoxication.

Pathology and functional disorders of the liver is almost always combined with the pathology of the gallbladder and biliary tract, and therefore is the most successful therapy, aimed at improving the metabolic processes in the liver, increasing its resistance to pathogenic influences, to accelerate the recovery of its functions in various injuries, and the elimination of dysfunctional disorders of the biliary tract.

Currently, to protect the liver from the damaging effects of exogenous and endogenous factors in the official and folk medicine commonly used drugs of plant origin.

The most famous hepatoprotectors, containing active substances, milk Thistle fruit (Kars, legal, zelibor, si is the IMAR, silymarin and other), as well as complex drugs, where milk Thistle is one of the ingredients (cybertan, margali, hepabene and others).

Widespread in recent years in the group of hepatoprotectors received essential phospholipids. Phospholipids are a major component of intercellular and cell membranes. The membrane of the hepatocytes of the liver (65% consist of phospholipids and their presence plays a key role in the implementation of the biological functions of membranes. When the deficiency of essential phospholipids is degeneration of the liver.

Known drug "Essentiale N" capsules containing 300 mg essentilly phospholipids and excipients (REFERENCE VIDAL drugs in Russia: a Handbook. M: Attraversare, 2006, SB-1241).

Known composition according to the patent of Russian Federation №2133122, which contains phospholipids and glycyrrhizinic acid or its salts and excipients.

In the patent of Russian Federation №2283114 described hepatoprotective composition comprising a phospholipid, both vegetable and animal origin, essential amino acid, preferably methionine or threonine, and a filler.

The closest analogue of the claimed composition is the drug "asslover Forte capsules. This product contains 300 mg of essential phospholipids, vitamin B16 mg, vitamin B26 mg, VI is Amin 66 mg, vitamin B126 mg, tocopherol acetate 6 mg, nicotinamide 30 mg (REFERENCE VIDAL drugs in Russia: a Handbook. M: Attraversare, 2006, SB-1242). Used for liver diseases of various etiologies as hepatoprotector.

The disadvantage of the prototype is its narrow pharmacological orientation.

It is noted that in recent times due to increased life expectancy increases the number of people with comorbidity requiring simultaneous appointment of a number of medicines that causes certain problems for the patient at their reception.

The objective of the invention is to create a new hepatotropic herbal remedies with a wide pharmacological spectrum of action.

The technical result is an extension of the pharmacological action of the product is due to the combination of anti-inflammatory, hepatoprotective, choleretic and detoxifying activity.

The proposed means of having hepatoprotective, detoxifying and regenerating effect, contains essential phospholipids, vitamin B1, vitamin b2vitamin B6, vitamin E, extract, milk Thistle, artichoke extract and excipients in the following ratio, wt.%:

essential phospholipids
30-60
extract of milk Thistle12-24
artichoke extract12-24
vitamin B10,23
vitamin b20,27
vitamin b60,3
vitamin E1,5
excipientsup to 100.

Essential phospholipids in the specified tool is represented mainly phosphatidylcholine, which is the main phospholipid, forming part of lecithin. Many held under double-blind control studies (Kidd P.M. Dietary Phospholipids as Anti-aging nutraceuticals. In: Klatz R. A., R. Goldman etc Anti-aging medical therapeutics, vol. IV. Chicago, 2000: 282-300) indicate a high efficiency of application of phosphatidylcholine with liver disease of viral or toxic origin. As the main phospholipid of cell membranes, phosphatidylcholine serves as a building block responsible for their recovery. On the other hand, due to the presence in the molecule Kalinovo group, phosphatidylcholine provided the t liver other important for its regeneration components: metal groups, necessary for the maintenance of many metabolic processes and gene duplication prior to cell division. Phosphatidylcholine is safe and well tolerated even when taking several grams per day. In the inventive tool is essential phospholipids contained in the amount of 100.0-200.0 mg per capsule, when the content of phosphatidylcholine 78%.

Milk Thistle (Silybum marianum G., Compositae) is a plant of the family Compositae. The main active principle of the fruits of milk Thistle is the sum of flavolignans the joint name of silymarin. Silymarin inhibits lipid peroxidation, resulting prevents damage to cell membranes. The drugs Thistle have a hepatoprotective effect, improves metabolic processes in the liver, promote the formation of bile and its flow (Sokolov, SJ Phytotherapy and pharmacology: a guide for physicians. M: Medical information Agency, 2000 C). Extract, milk Thistle is included in the inventive composition in an amount of 40.0-80.0 mg per capsule.

Artichoke planting or field (Apaga scolymus L., Compositae) is a plant of the Asteraceae family, is used in food. The artichoke contains 3% protein, 10-15% carbohydrates, ascorbic acid, vitamins, carotene, inulin and tsinarin. Contained in the plant tsinarin has choleretic, anticipated cichecki and diuretic (Sokolov, SJ Phytotherapy and pharmacology: a guide for physicians. M: Medical information Agency, 2000 C). Inulin, which is part of the artichoke, increases the secretion of bile, and tannins contribute to the provision of anti-inflammatory effect. Increasing bile flow and good its outflow promote excretion from the liver of toxins. Artichoke extract is included in the inventive composition in an amount of 40.0-80.0 mg per capsule.

The vitamins in the inventive composition is taken as the recommended daily doses. In the use of funds in the recommended dose (2 capsules per day) in the human body will do at least 10 mg of vitamin E (70-100% adequate level of consumption), not less than 1.5 mg of vitamin B1(90-100% adequate level of consumption), 1.8 mg of vitamin b2not less than 2 mg of vitamin b6(recommended daily intake), at least 40 mg flavolignans milk Thistle is within the acceptable daily intake levels (up to 80 mg / day) (SanPiN 2.3.2.1078-01, Mr 2.3.1.191-04).

B vitamins are involved in the metabolism of proteins, fats, carbohydrates, have a positive effect on the functional state of the liver.

Vitamin E has antioxidant properties, i.e. protects the lipids of cell membranes (including liver cells) from peroxidation and free radical damage.

A separate application is the component of the proposed drug in the prior art it is known, however, they share a single drug to a specified destination (hepatotropic tool) is unknown.

The authors have found good compatibility and synergism of action of essential phospholipids, an extract of milk Thistle and artichoke extract. Plants and their ratio in the composition are selected so that they complement each other. Complex flavolignans milk Thistle is most effective in combination with cynarina artichoke. The vitamins included in the proposed drug function as coenzymes in various biochemical processes and potentiate the effect of essential phospholipids.

Thus, component composition, combining natural hepatoprotector milk Thistle with normalizing the secretion and flow of bile artichoke enriched with essential phospholipids, repairosome cell membrane, and potentiating their vitamins, determines detoxifying, anti-inflammatory, hepatoprotective, choleretic and regenerating action orientation funds. Thus, the claimed technical result.

The result is a rational combination of the components of the received tool that replaces a number of medicines. Given that liver disease is almost always combined with zhelchesekretornoyj pathology that requires simultaneous is the purpose of a number of medicines, the tool will be in demand in the market.

Declared in the composition of the number of active ingredients have a supportive therapeutic effect in adjuvant therapy, as well as in primary or secondary prevention of liver diseases.

The combination of the novelty of the composition and a wide pharmacological actions speaks about the criteria of "novelty" and "inventive step".

An additional advantage of the proposed drug is no toxicity, allowing it to be used for a long courses as a standalone tool, normalizing the function of the hepatobiliary system, and as an adjuvant along with traditional therapy or in the recovery period after illness.

Examples of specific performance

Example 1. Capsules weight of 0.33,

essential phospholipidsof 0.1±0.01 g
extract of milk Thistle0,05±0.005 g
artichoke extract0,045±0.005 g
vitamin B10,00075±0.00015 grams
vitamin b20,0009±0,00018 g
of 0.001±0.0002 g
vitamin Eof 0.005±0.001 g
MCC or starch0,09235±0.0005 g
calcium stearate or magnesium stearate0,005±0.0005 g
Aerosil0,015±0.0015 g
talc0,015±0.0015 g

Example 2. Tablet weight of 0.5,

essential phospholipidsof 0.1±0.01 g
extract of milk Thistle0,045±0.005 g
artichoke extract0,045±0.005 g
vitamin B10,00075±0.00005 g
vitamin b20,0009±0.0001 g
vitamin B6of 0.001±0.0005 g
vitamin E0,005±0.0005 g
MCC or starch0,290±0.005 g
calcium stearate or magnesium stearate 0,0025±0.0005 g
Aerosil0,010±0.005 g

To assess the effectiveness of funds in complex therapy of diseases of the liver and biliary tract in conditions of the outpatient unit of the MUSES "Diagnostic center" griska was conducted surveillance of 40 patients with chronic liver disease and bile ducts (biliary dyskinesia, chronic cholecystitis, hepatitis And in the stage of convalescence).

In the clinical examination included 20 patients who received the proposed tool (study group)and 20 patients who were not receiving it and formed the control group. Patients comparison groups were equivalent in the sex-age structure of disease, presence of comorbidity. The observed received conventional therapy due to nosological form of the disease. The main group received additionally the inventive tool 1 capsule 2 times a day. The results of the observations were recorded in a standard form with an evaluation of the results at the beginning of the observation and 30 days.

The main criteria for assessing the effectiveness of therapy were: dynamics of clinical parameters, biochemical blood tests, ultrasound.

The results of the study presented is s in tables 1-3.

Table 1
Comparison of some clinical parameters in the dynamics (in %)
IndicatorsThe main groupThe control group
1 day30-day1 day30-day
Pain in the right hypochondrium100010010
Pain in the epigastric region5006010
Belching, nausea450455
Flatulence400505
Bitter taste in the mouth70075 0
Irregular bowel movements3003510
The palpation region of the liver 1-2 cm below the edge of the costal arch250305

From table 1 it is evident that patients of both groups came clear positive trend. But in the group of patients receiving in complex therapy of the inventive tool, the positive dynamics occurred somewhat earlier than in the control group.

Table 2
Dynamics of biochemical and cellular parameters of blood
IndicatorsThe main groupThe control group
1 day30-day1 day30-day
Total bilirubin, µmol/l23,5±4,316,3±3,427,3±5,6 21,4±2,6
Alat, mmol/l4,9±0,81,2±0,64,7±0,92,9±0,8
AST, mol/l4,2±0,91,2±0,44,0±0,83,7±0,4
Total cholesterol, mol/l6,6±1,85,4±1,56,4±0,66,2±1,6
Alkaline phosphatase, IU/l180,4±18,6110,0±10,4182,0±17,6140,2±14,4
ESR, mm/hour18,4±1,89,4±0,916,1±1,210,4±1,1
The leukocyte count, ×10914,4±1,17,6±0,615,2±0,99,4±0,6

Evaluation of blood parameters (see table 2) showed that most patients with an initial expression of cytolytic syndrome receiving the claimed means of normals is the situation of Alt was observed already by the end of the 3rd week, however, it was noted positive dynamics in all respects, and anti-inflammatory effect was more pronounced than in the control group.

Table 3
Comparative evaluation of ultrasound of the liver and biliary tract (%) in dynamics
IndicatorsThe main groupThe control group
1 day30-day1 day30-day
Liver
Dimensions: not modified75957085
increased2553015
Contours: clear80957585
fuzzy2052515
Echo: not modified70856580
improved30153520
Echostructure: not modified90908585
the presence of more. formations10101515
Bile ducts: not modified35903055
extended65107045
Gall bladderthe
Cavity: normal size25802060
extended75208040
Wall: not modified35604055
thickened65406045
Echo the contents of the gallbladder:
not changed10851565
increased availability of sediment90158535

From table 3 it can be seen that the analyzed after treatment decreased the size of the liver and gall bladder, has improved ehostruktura the contents of the gall bladder, the tendency has been to improve ehacardin liver structure. However, the positive trend was more pronounced in the group of patients treated with the inventive tool, as a consequence of increasing the flow of bile, reduce intrahepatic cholestasis.

Portability means was good throughout the monitoring adverse reactions have been identified.

Observations suggest the claimed means of complex pathogenetic means of providing an anti-inflammatory, hepatoprotective, antispasmodic and regulating the motility of the biliary tract action.

The advantage of the proposed drug is the reinforcement, the useful pharmacological properties of each incoming ingredient, its compliance with polivalentes pathogenesis of the disease, the impact on overall patient's body as a corrective system.

Considering the combined action of the inventive tool can be recommended for the provision of preventive and curative, both independently and optionally in combination with drugs in patients with acute and chronic liver diseases and biliary tract. The tool should be appointed from the first days of the illness : 1 tablet 2 times a day. The duration of treatment is not less than 30 days. It is advisable to treat the drug is not less than 3 months.

A means of having hepatoprotective, detoxifying and regenerating effect, contains essential phospholipids, vitamin B1, vitamin b2, vitamin b6vitamin E and excipients, characterized in that it further contains extract, milk Thistle and artichoke extract in the following ratio, wt.%:

essential phospholipids30-60
extract of milk Thistle12-24
artichoke extract12-24
vitamin B10,23
vitamin b20,27
vitamin b60,3
vitamin E1,5
excipients100



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science, namely to therapy of internal non-transmitting diseases, particularly to drugs for pig hepatosis prevention. The agent for pig hepatosis prevention contains the ingredients in the following relation: antihepatotoxic serum 0.9-1.15 titre units; antisplenotoxic serum 0.9-1.15 titre units; leukocyte plasma 90-110 embryo units; phenol 0.004-0.005 mg; physiologic saline up to 1 ml.

EFFECT: invention allows higher effectiveness of pig hepatosis prevention.

4 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of general formula (I) , where the dotted line is either absent or denotes a double bond; R1 denotes H or C1-6-alkyl, possibly substituted with a CN group, or denotes a phenyl or sulphonyl phenyl, substituted with one or more B groups, or denotes -(CH2)m-Ra, where Ra denotes: NRiRii, C3-6-cycloalkyl, 6-member heterocycloalkyl, which denotes a univalent saturated group which contains one nitrogen heteroatom, the rest are carbon atoms, aryl, which can be substituted with one or more B groups, or denotes -(CH2)n-(CO)-Rb or -(CH2)n-(SO2)-Rb, where Rb denotes: NRiRii, 5-6-member heterocycloalkyl, which denotes a univalent saturated group containing one or more heteroatoms selected from nitrogen, oxygen, the rest are carbon atoms, aryl or 5- or 6-member heteroaryl, which denotes an aromatic ring containing two heteroatoms as ring members, the said heteroatoms selected from N or O, the rest are carbon atoms; which can possibly be substituted with one or more B groups, R2 denotes one or more H, halo, C1-6-alkyl, C1-6-alkoxy, R3 denotes H or-(CO)-Rc, where Rc denotes: C1-6-alkyl, 5-member heterocycloalkyl, which denotes a univalent saturated group containing one nitrogen heteroatom, the rest are carbon atoms possibly substituted with C1-6-alkyl, or denotes C1-6-alkyl; R4 denotes H; R5 denotes H, C1-6-alkyl, -(CH2)m-NRiRii, -(CH2)n-(CO)-Rb, where Rb denotes NRiRii or a 6-member heterocycloalkyl which denotes a univalent saturated group which contains one nitrogen heteroatom, the rest are carbon atoms, when the dotted line is absent or is absent when the dotted line denotes a double bond; R6 is absent, when the dotted line denotes a double bond; R7 denotes Cl or NReRf, where Re and Rf denotes H or C1-6-alkyl, or Re and Rf together with the nitrogen atom to which they are bonded form a 6-member heterocycloalkyl which denotes a univalent saturated group containing one or two heteroatoms selected from nitrogen, oxygen, the rest are carbon atoms; which can be substituted with C1-6-alkyl, or R6 and R7 together form a C=O group, when the dotted line is absent; B denotes halogen, C1-6-alkoxy, (CRiiiRiv)n-phenyl; Ri and Rii denote H, C1-6-alkyl -C(O)-C1-6-alkyl; Riii and Riv denote C1-6-alkyl; m equals to 1 or 2, n equals 0 or 1; as well as to pharmaceutically acceptable salts thereof. The invention also relates to a pharmaceutical composition, as well as to use of compounds of formula (I), (I-a) or (1-b).

EFFECT: obtaining novel biologically active compounds having activity on V1a receptor.

12 cl, 48 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new oxoazepanylacetamide and oxoazepanylphenoxyacetamide derivatives, or to their stereoisomers or pharmaceutically acceptable salts described by general formula I where Q means O, S or N(R25); R25 means H; R80 is C6arylC1-4alkyl substituted by one or two substituted independently chosen from R3 groups; each R3 is independently chosen from a group including C1-4alkyl, C1-4alkoxy group, C2-6alkenyloxy group, halogen, C6aryloxy group, N(R20)(R21), R50, heteroaryl chosen from pyridine and thiazol where each alkoxy group and heteroaryl has optionally up to three substitutes independently chosen from R61 groups; and alkyl has optionally three substitutes independently chosen from R60 groups; or two R3 groups when they are present on carbon neighbours, together can form a fragment of formula -(O)a-(CH2)b-(O)c-(CH2)d-(O)e- where a, c and e independently mean 0 or 1, and both b and d independently mean 0, 1, 2 or 3; provided the fragment does not contain two oxygen neighbors and summed a, b, c, d and e are equal to 3 at least; R1 is chosen from a group including H, C1-4alkyl, C6arylC1-4alkyl; each R60 independently is chosen from a group including C1-C6a alkoxy group, NR12R13, halogen, heterocycloalkyl, such as piperidine; each R61 independently is chosen from a group including R60 and C1-C6alkyl; X means a group of formula -(CH2)n- where n means 2 or 3; or a group of formula II where Y means CH2, S; R75 and R76 means H; Z means C6aryl or heteroaryl, such as pyridine; each of which has optionally one substitutes chosen from R2 groups; R2 is chosen from a group including H, C1-4alkyl, halogen, heterocycloalkylC1-4alkyl, C6arylC1-4alkylaminoC1-4alkyl and a group of formula -(CH2)fN(R11)-(R10); where each heterocycloalkyl, arylalkylaminoalkyl has oprtionally one substitute chosen from R61 groups; f means 1; R11 means H; R10 means C1-6alkyl, C2-6alkenyl, C3-8cycloalkyl, aryl, C6arylC1-4alkyl, heteroarylC1-4alkyl where aryl has optionally one substitute chosen from R61 groups; each R12 and R13 independently mean C1-4alkyl; each R20 and R21 independently mean C1-4alkyl where alkyl has optionally one substitute chosen from R60 groups; and provided that the compound does not represent N-(4-ethoxybenzyl)-N-(2-oxoazepane-2-yl)-2-phenoxyacetamide or N-[(2-fluorophenyl)methyl]-N-(2- oxoazepane-3-yl)-2,2-diphenylacetamide. Also, the invention refers to a pharmaceutical composition of the compound of formula I, to methods of treating HCV viral infection and methods of relieving the symptoms of HCV viral infection with using the compound of formula I.

EFFECT: there are produced new oxoazepanylacetamide and oxoazepanylphenoxyacetamide derivatives showing HCV replication inhibiting activity.

1 tbl, 9 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of formula (I), where R2 denotes H, [(C1-C6) alkylene]0-1-R'; R3 denotes H; R4 denotes H, halogen or (C1-C6) alkyl; R5 denotes H or halogen; R6 denotes H, (C1-C8) alkyl, R', (C1-C6) alkylene-R'; R7 and R8 independently denote H, halogen, (C1-C6) alkyl, O-(C1-C6) alkyl, R'; R9 denotes (C1-C6)alkyl; n equals 0 or 1; L denotes O or O-(C1-C6)alkylene; where R' denotes (C3-C8) cycloalkyl; (C5-C10)heterocyclyl, which denotes an aromatic or saturated mono- or bicyclic ring system which, besides a carbon atom, includes one or more heteroatoms such as nitrogen, oxygen and sulphur atoms; or (C6-C10) aryl; where in the heterocyclyl is unsubstituted or substituted with (C1-C6)alkyl, and the aryl is unsubstituted or substituted with a halogen, (C1-C4)alkyl, -O-(C1-C4)alkyl, SO2- (C1-C4) alkyl or N[(C1-C4) alkyl]2; and where in groups R4, R6 and R7 the alkyl can be halogenised in one or more positions; or pharmaceutically acceptable salts and/or stereo isomer forms thereof. The invention also relates to use of formula (I) compounds, as well as a medicinal agent.

EFFECT: obtaining novel biologically active compounds having Rho-kinase inhibiting activity.

21 cl, 320 ex, 3 tbl

FIELD: medicine, veterinary science.

SUBSTANCE: invention refers to veterinary science, namely to therapy of internal nontransmitting diseases, particularly to drugs for chicken hepatosis prevention. The agent for chicken hepatosis prevention contains the ingredients in the following relation: antihepatotoxic serum 0.9-1.15 titre units; antisplenotoxic serum 0.9-1.15 titre units; phenol 0.004-0.005 mg; physiological solution up to 1 ml. The agent is introduced to chickens and chicks in dose 0.2 ml/kg of body weight subcutaneously or intramuscularly.

EFFECT: invention allows higher effectiveness of chicken hepatosis prevention.

4 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to hepatology, and can be applied in treatment of chronic hepatitis, caused by TTV virus. Method consists in simultaneous application of medication Amixin 0.125 in dose 1 pill every second day during 3 months in combination with medication fosfogliv in dose 2 pills 3 times per day during 3 months, with simultaneous treatment of sex partner.

EFFECT: application of invention allows to reach eradication of TTV form patient's organism with reduction of treatment time and reduction of complication quantity.

1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to pharmacology and cell technologies. Medication, possessing regenerative activity, represents granulocytic colony-stimulating factor, immobilised on water-soluble polymers with molecular weight 400-4000 Da. Granulocytic colony-stimulating factor is immobilised on water-soluble polymers by means of ionising radiation - flow of accelerated electrons with energy 2.5 MeV, absorbed dose from 2 to 10 kGy and rate of dose gain 1.65 kGy/hour.

EFFECT: medication by claimed invention does not have immunogenicity, is highly efficient both in parenteral and peroral introduction.

10 tbl, 10 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to pharmacology. An agent represents an aqueous solution of molecularly capsulated dihydroquercetin in the form of a water-soluble associate. Dihydroquercetin is homogenised in a melted surfactant or in a general solvent ethanol in the relation of the surfactant to dihydroquercetin 5:1 in a temperature range 40-70°C to be mixed with water and concentrated by water evaporation.

EFFECT: invention allows higher bioavailability and activity of the agent, simplified technology.

4 cl, 3 ex, 3 tbl, 8 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, in particular to hepatoprotective medication. Medication, which has hepatoprotective action, represents product of extraction by ethanol of thalli of Cha-Kombu - Laminaria japonica Aresch., of laminarian family -Laminariaceae, which contains to 30 % of polyphenol compounds.

EFFECT: medication possesses efficient hepatoprotective action, favours accelerated restoration of metabolic reactions cascade, ensuring normalisation of biochemical characteristics of carbon and lipid exchange, as well as endogenous antioxidant protection system.

6 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to abdominal surgery, and is intended for purulent cholangitis treatment. The method includes draining and flushing of common bile duct with antiseptic agent. Miramistin solution is used as such agent, which is injected into common bile duct 2-3 times a day during 3-10 days.

EFFECT: invention enables to avoid adverse cytotoxic effect on tissues of hepatobiliary system, improve efficiency of local antibiotic treatment of cholangitis, including due to increased sensitivity of cholangitis germs to endogenous antimicrobial peptide protein.

2 ex, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry, namely to creation of medication, which possesses anti-inflammatory and regenerating action. Medication contains the following ingredients: conifer needle extract, purified oleoresin of cedar or pine, or spruce, or fir, or larch or their mixture in equal proportions, vegetable oil.

EFFECT: medication has increased effectiveness and efficiency and also extends arsenal of medications, which have anti-inflammatory and regenerating action.

7 cl, 9 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: invention relates to chemical-pharmaceutical industry, namely, to method of obtaining preparation, which has immunomodulating, anti-inflammatory and wound-healing action, which lies in crushing preparation components dog rose fruit and/or ambrosia, drying to 10% humidity, freezing ambrozia and/or dog rose fruit separately to temperature 40-60°C with further impact on each component in jet mill by air jet under pressure 0.6-0.8 MPa until particles with size not more than 500 nm are obtained.

EFFECT: method ensures high productivity and good preservation of material properties.

2 tbl, 9 ex, 2 cl

FIELD: medicine.

SUBSTANCE: invention relates to cosmetology and represents cosmetic preparation, which contains derivative of vitamin E as a solubilising agent, represented by given below formula or its salt: where R1, R2 and R3 independently represent hydrogen atom or methyl group; R4 represents hydrogen atom, alkanoyl group which has from 1 to 6 carbon atoms, alkyl group, which has from 1 to 6 carbon atoms, group SO3H, group P(O)(OH)2, group CH2COOH or group COCH2 CH(SO3H)COOH; EO represents ethylene oxide group; BO represents butylene oxide group; k and n independently represent any of the numbers from 0 to 30 (however, k and n simultaneously do not take 0 value; and m represents any of the numbers from 0 to 30 and components, which are usually applied in cosmetic preparations.

EFFECT: invention ensures absence of stickiness during drying after application on skin, as well as improvement of solubilising and emulsifying ability.

7 cl, 13 ex, 5 tbl, 1 dwg

FIELD: medicine.

SUBSTANCE: invention relates to field of cosmetics. Composition, including, at least, one active component, selected from, at least, one antiperspirant active component and, at least, one deodorant active component, first gel-forming agent, selected from, at least, one fatty alcohol and, at least, one hydrocarbon of formula CnH2n+2, in which n has value from approximately 20 to approximately 100, and hydrocarbon, at least for 90% has linear structure; at least, one soya oil, which has iodine number from 0 to approximately 20; and, at least, one silicon-organic compound.

EFFECT: invention ensures antiperspirant and esthetic effect, without leaving visible deposit.

9 cl, 8 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of cosmetics. Composition, including, at least, one active component, selected from, at least, one antiperspirant active component and, at least, one deodorant active component, first gel-forming agent, selected from, at least, one fatty alcohol and, at least, one hydrocarbon of formula CnH2n+2, in which n has value from approximately 20 to approximately 100, and hydrocarbon, at least for 90% has linear structure; at least, one soya oil, which has iodine number from 0 to approximately 20; and, at least, one silicon-organic compound.

EFFECT: invention ensures antiperspirant and esthetic effect, without leaving visible deposit.

9 cl, 8 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of cosmetics. Composition, including, at least, one active component, selected from, at least, one antiperspirant active component and, at least, one deodorant active component, first gel-forming agent, selected from, at least, one fatty alcohol and, at least, one hydrocarbon of formula CnH2n+2, in which n has value from approximately 20 to approximately 100, and hydrocarbon, at least for 90% has linear structure; at least, one soya oil, which has iodine number from 0 to approximately 20; and, at least, one silicon-organic compound.

EFFECT: invention ensures antiperspirant and esthetic effect, without leaving visible deposit.

9 cl, 8 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of cosmetics. Composition, including, at least, one active component, selected from, at least, one antiperspirant active component and, at least, one deodorant active component, first gel-forming agent, selected from, at least, one fatty alcohol and, at least, one hydrocarbon of formula CnH2n+2, in which n has value from approximately 20 to approximately 100, and hydrocarbon, at least for 90% has linear structure; at least, one soya oil, which has iodine number from 0 to approximately 20; and, at least, one silicon-organic compound.

EFFECT: invention ensures antiperspirant and esthetic effect, without leaving visible deposit.

9 cl, 8 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine, namely to dentistry, and deals with medications for restoration of periodontal tissues and methods of their obtaining. Biotransplant for treatment of periodontal diseases represents suspension which contains cultures of autological or allogenic fibroblasts, or fibroblast-like cells in 0.9% solution of sodium chloride in concentration 2.0-10.0x106 in 1 ml of biotransplant, integrated on pharmaceutically acceptable biocompatible biodegradable carrier, selected from the group: acellular matrix, hyaluronic acid preparation, acellular matrix and hyaluronic acid preparation, with specified volume ratio of cell culture suspension ands carrier, which makes it possible to obtain consistence convenient for injecting and, together with expressed clinical effect ensures low traumaticity and simplicity of injecting. Preferable, as carrier, used is crushed to size 100-200 mcm acellular matrix "Saimetra". Also claimed is method of treating periodontal diseases, which lies in the following: on mucous membrane of gum in region of defect one week before biotransplant introduction preliminarily made are cuts provoking an acute inflammatory process resulting in increase of tissue volume, which makes it possible to carry out lossless introduction of large volume of biotransplant. After that, into defect area by means of injection two times with interval 1-4 weeks introduced is claimed biotransplant, using 3.6-60×106 cells per treatment course, which ensures optimal time interval for cell engraftment and restoration of periodontal tissues.

EFFECT: increase of treatment efficiency.

7 cl, 3 ex, 2 dwg

FIELD: food industry.

SUBSTANCE: method involves preparation of inoculation mycelium of basidiomycetes, preparation of productive nutrient medium and inoculation of the productive nutrient medium, containing carbohydrate and nitrogen source and mineral salts, with the prepared inoculation mycelium. Basidiomycetes cultivation with subsequent production of an immersion culture. The inoculation mycelium preparation is performed in a sterile nutrient medium containing glucose, soya flour, potassium dihydrogen phosphate, magnesium sulphate and arachidonic acid. The inoculation mycelium growing is performed at a temperature of 22-29°C during 2-6 days under aeration conditions with its subsequent homogenisation.

EFFECT: antineoplastic remedy produced from the basidiomycetes immersion culture is effective and the cultivation process duration is reduced from 2-3 weeks to one week; mycelium yield increases.

23 cl, 6 tbl, 12 ex

FIELD: chemistry.

SUBSTANCE: disclosed is a copolymer containing silicon groups, obtained via radical copolymerisation of at least one compound with radically polymerisable α,β-ethylene-unsaturated double bond and at least one ionogenic and/or ionic group per molecule; and at least one radically polymerisable cross-linked compound, which contains at least two α,β-ethylene-unsaturated double bonds per molecule in the presence of at least one organosilicon compound containing a polyether group and/or urethane(meth)acrylate, which contains siloxane groups. The copolymer has molar excess of anionogenic/anionic groups relative cationogenic/cationic groups. The invention also discloses a method of obtaining said copolymer and a cosmetic or pharmaceutical agent containing said copolymer.

EFFECT: powder can be easily added to thickening compositions and is suitable for modifying rheological characteristics of cosmetic and pharmaceutical compositions.

18 cl, 2 tbl, 90 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to hepatology, and can be applied in treatment of chronic hepatitis, caused by TTV virus. Method consists in simultaneous application of medication Amixin 0.125 in dose 1 pill every second day during 3 months in combination with medication fosfogliv in dose 2 pills 3 times per day during 3 months, with simultaneous treatment of sex partner.

EFFECT: application of invention allows to reach eradication of TTV form patient's organism with reduction of treatment time and reduction of complication quantity.

1 tbl, 3 ex

Up!